BGPT: Paper Review: Robustness and reproducibility for AI learning in biomedical sciences: RENOIR

Fuel Your Discoveries

Quick Explanation Copied

RENOIR

RENOIR is an open-source, modular framework aimed at making biomedical ML results more robust and reproducible by combining nested repeated sampling, training-set-size sensitivity, optional feature screening, and automated interactive reporting.

Long Explanation

Paper Review (Evidence-based, Skeptical, Visual): “Robustness and reproducibility for AI learning in biomedical sciences: RENOIR”

DOI: 10.1038/s41598-024-51381-4 Journal: Scientific Reports Received/Accepted: 18 Jul 2023 / 4 Jan 2024

Core claim: RENOIR improves robustness/reproducibility of biomedical ML learning by standardizing evaluation (incl. training-set-size dependence via repeated sampling), enabling uncertainty quantification, avoiding leakage via pipeline-integrated screening, and generating transparent interactive reports.

1) Visual map: what RENOIR does (from the paper’s workflow description)

Workflow nodes and edges are taken from the paper’s “RENOIR workflow” description (pre-processing → nested repeated sampling across training sizes → feature-importance computation → interactive reports) and supporting descriptions of optional supervised screening, hyperparameter tuning (incl. 1SE), and uncertainty quantification via confidence intervals.

2) Training-set-size sensitivity: what’s evaluated?

The paper emphasizes that performance estimates should account for variability induced by training-set size and split randomization, rather than assuming a fixed-size split (e.g., a single k-fold choice).

2a) Reported training-set sizes used in the paper’s exemplars

Breast cancer exemplar training sizes: 342, 426, 510, 594, 681. SETD2 methylation exemplar training sizes: 20, 46, 72, 98. Drug efficacy exemplar training sizes: 172, 257, 342.

3) Quantitative robustness signals shown in the paper (from the provided text)

3a) Drug-response use case: training-set-size-dependent mean squared error (MSE) ranges

The paper explicitly reports approximate MSE ranges for random forest, lasso, ridge, and elasticnet over training sizes (reported as ranges in the provided text). These values are used below only as paper-reported bounds; no additional inference is added.

3b) Method selection may differ across train vs test

The paper describes a pattern: random forest can look best on training/full sets, yet test performance may degrade for smaller training sizes and may not outperform others consistently—signaling the necessity of the evaluation design (and not trusting training-only performance).

4) What the paper is trying to fix (and what’s still uncertain)

4a) Problems addressed (known from the paper)

Reproducibility gaps: the paper argues that missing code/dataset, missing methodological details, and incomplete reporting undermine replication; it positions RENOIR as a pipeline/reporting solution for the learning phase.
Over-optimistic estimates: the paper links biased results to improper split usage and leakage via supervised feature screening done before splitting. RENOIR integrates supervised screening after sampling into independent training/validation/test sets.
Instability from training size / split choice: RENOIR evaluates performance across multiple training set sizes and repeats random splits to quantify mean and uncertainty (95% CI).

4b) Skeptical blind spots / known unknowns (what we can’t confirm from the provided text)

External validity strength is underspecified here. The review text provided includes claimed results for SETD2 and mentions external validation (87% accuracy) and notes test-set deterioration in the drug use case, but it does not provide the full experimental design for every model, dataset preprocessing, or complete statistical reporting for all comparisons.
Feature screening choices may change outcomes. RENOIR supports unsupervised screening and optional supervised screening (empirical Bayes moderated t-statistics / permutation tests are mentioned), but the sensitivity of final results to particular screening thresholds, variability metrics, and hyperparameter grids is not fully reconstructible from the excerpt.
Model class coverage is pragmatic, not universal. The framework (in the paper’s described examples) supports a set of learning methods (e.g., penalized generalized linear models, random forests, SVM, boosted models, generalized kNN). That’s useful—but it may not address robustness issues unique to other architectures (e.g., deep nets with different failure modes) unless those are supported/validated in additional materials beyond the excerpt.

5) Visual checklist: what to verify when using RENOIR (reproducibility audit mindset)

Audit item	What the paper says RENOIR does	What you should still check in practice
Split integrity	Nested repeated sampling with train/test splits across sizes; supervised screening is after sampling splits.	Confirm that every feature-selection/preprocessing operation is inside the training-fold only when applicable; validate no test leakage via configuration logs.
Uncertainty quantification	Estimates mean performance and 95% confidence intervals from repeated samples.	Check whether CI computation uses the intended sampling distribution assumptions; ensure enough repeats so CI is stable.
Model selection bias	Hyperparameter tuning uses grid search with 1SE option; best model selection uses training-set-size CI bounds.	Verify the selection metric matches the intended scientific target (e.g., calibration vs discrimination) and examine sensitivity to the selection rule.
Traceability	Generates interactive reports including methods, sampling, metrics, confusion matrices/ROC/PCA/feature distributions.	Confirm report outputs include all parameters/configuration seeds required to exactly re-run experiments.

6) Conclusion (with confidence & falsifiability)

6a) Main takeaway (what is well supported by the paper excerpt)

RENOIR operationalizes a concrete, repeatable evaluation philosophy for biomedical ML: treat training-set size and random split assignment as first-class sources of variability; estimate mean performance and uncertainty via repeated sampling; and reduce optimistic bias by integrating feature screening within the split-aware pipeline.

6b) What would most disprove the implied benefit

If independent groups using RENOIR’s pipeline (with comparable configuration discipline) still fail to obtain reproducible and better-generalizing results across multiple external cohorts—especially under deliberately shifted domain conditions—then the practical advantage of the framework over conventional evaluation would be weakened. The paper itself acknowledges generalization challenges via the observed test-set deterioration behavior in the bortezomib example.

Next: author-specific reviews (for deeper critique)

Feedback:

Updated: March 24, 2026